In support of this notion, multiple previous studies observed that tumor cells obtained from Burkitt lymphoma, double-hit B cell lymphoma, and triple-negative breast cancer are largely insensitive to EZH2 enzymatic inhibitors9,37,38. Here, EZH2 is linked to triple-negative breast carcinoma.